Loading
A single protein predicts whether a tumour will respond to DNA-damaging drug payloads. Measuring it could stop patients receiving a second drug of the same kind that will not work.
SLFN11 expression predicts sensitivity to topoisomerase 1 inhibitors and platinum across preclinical models and some clinical series, and its loss is a recognised mechanism of payload resistance. With most current ADCs carrying topoisomerase 1 payloads, SLFN11 immunohistochemistry on a progression biopsy could distinguish antigen-driven from payload-driven failure and direct patients to a different payload class such as a tubulin inhibitor.
Shares Sequencing HER2 ADCs by payload after T-DXd, Payload-class switching as the rule for ADC sequencing, ADC sequencing, Acquired resistance to every therapy.
Shares ADC sequencing, Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares ADC sequencing, Acquired resistance to every therapy.
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
Shares Payload-class switching as the rule for ADC sequencing, ADC sequencing, Biomarkers are not validated or standardised, Topoisomerase-I inhibitors (and ADC payloads).
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Histopathology & immunohistochemistry, Antibody-drug conjugate (ADC).
Shares Payload-class switching as the rule for ADC sequencing, ADC sequencing, Payload (ADC), Acquired resistance to every therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/